Beyond compliance: The strategic role of PASS in rare disease therapy success
Post-authorisation safety studies (PASS) are often seen simply as a regulatory necessity, a checkbox that ensures ongoing monitoring of a treatment’s safety. However, for biotech and pharma focused on developing rare disease therapies, PASS can be so much more. The post Beyond compliance: The strategic role of PASS in rare disease therapy success appeared first on Medical Device Network.
Post-authorisation safety studies (PASS) are often seen simply as a regulatory necessity, a checkbox that ensures ongoing monitoring of a treatment’s safety. However, for biotech and pharma focused on developing rare disease therapies, PASS can be so much more.
The post Beyond compliance: The strategic role of PASS in rare disease therapy success appeared first on Medical Device Network.
